Christopher McDermott

13.1k total citations · 1 hit paper
221 papers, 6.0k citations indexed

About

Christopher McDermott is a scholar working on Neurology, Genetics and Neurology. According to data from OpenAlex, Christopher McDermott has authored 221 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 150 papers in Neurology, 97 papers in Genetics and 22 papers in Neurology. Recurrent topics in Christopher McDermott's work include Amyotrophic Lateral Sclerosis Research (139 papers), Neurogenetic and Muscular Disorders Research (97 papers) and Parkinson's Disease Mechanisms and Treatments (34 papers). Christopher McDermott is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (139 papers), Neurogenetic and Muscular Disorders Research (97 papers) and Parkinson's Disease Mechanisms and Treatments (34 papers). Christopher McDermott collaborates with scholars based in United Kingdom, United States and Netherlands. Christopher McDermott's co-authors include Pamela J. Shaw, Shikhar Sarin, Esther Hobson, Pierre‐Richard Agénor, Eswar Prasad, Joseph M. Mylotte, Janine Kirby, Theocharis Stavroulakis, Theresa Walsh and Stephen B. Wharton and has published in prestigious journals such as The Lancet, PLoS ONE and Brain.

In The Last Decade

Christopher McDermott

206 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD)

2024 43 citations Ammar Al‐Chalabi, Mamede de Carvalho et al. European Journal of Neurology profile →

Peers

Countries citing papers authored by Christopher McDermott

Since Specialization

Citations

This map shows the geographic impact of Christopher McDermott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher McDermott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher McDermott more than expected).

Fields of papers citing papers by Christopher McDermott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher McDermott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher McDermott. The network helps show where Christopher McDermott may publish in the future.

Co-authorship network of co-authors of Christopher McDermott

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher McDermott. A scholar is included among the top collaborators of Christopher McDermott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher McDermott. Christopher McDermott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploring the needs and preferences of people with amyotrophic lateral sclerosis (ALS) when making genomic testing decisions: an interview study 2025 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·(unknown), Hilary Bekker, Christopher McDermott, Alisdair McNeill	1
2	Development of a novel patient reported outcome measure for health-related quality of life in amyotrophic lateral sclerosis (PROQuALS): study protocol 2024 ·Health and Quality of Life Outcomes ·Jill Carlton, Philip A. Powell, Donna Rowen, (unknown), Alys Wyn Griffiths, Esther Hobson, Christopher McDermott	0
3	Exploring the role of anthropometric measurements to assess nutritional status in amyotrophic lateral sclerosis: a longitudinal prospective cohort study 2024 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·(unknown), Scott P. Allen, Christopher McDermott, Theocharis Stavroulakis	0
4	Measuring Health-Related Quality of Life in Amyotrophic Lateral Sclerosis 2024 ·Neurology ·(unknown), Jill Carlton, Philip A. Powell, Elizabeth Coates, Liam Knox, Emily Mayberry, (unknown), Alys Wyn Griffiths, Esther Hobson, Christopher McDermott	3
5	Mapping the Evidence for Measuring Energy Expenditure and Indicating Hypermetabolism in Motor Neuron Disease: A Scoping Review 2024 ·Nutrition Reviews ·(unknown), Scott P. Allen, Christopher McDermott, Theocharis Stavroulakis	1
6	Diagnostic delay in amyotrophic lateral sclerosis 2023 ·European Journal of Neurology ·Kelly Gwathmey, Philippe Corcia, Christopher McDermott, Angela Genge, Stefan Sennfält, Mamede de Carvalho, Caroline Ingre	26
7	Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis 2023 ·Translational Neurodegeneration ·Peter J. Richardson, Daniel P. Smith, Alex de Giorgio, (unknown), (unknown), (unknown), Richard J. Mead, Christopher McDermott, Pamela J. Shaw	15
8	Factors influencing decisions people with motor neuron disease make about gastrostomy placement and ventilation: A qualitative evidence synthesis 2023 ·Health Expectations ·Sean White, Alicia O’Cathain, Vanessa Halliday, Liz Croot, Christopher McDermott	10
9	A critical view of the use of predictive energy equations for the identification of hypermetabolism in motor neuron disease: A pilot study 2023 ·Clinical Nutrition ESPEN ·(unknown), (unknown), (unknown), Charmaine Childs, C. Elizabeth Weekes, Stephen A. Wootton, Scott P. Allen, Christopher McDermott, Theocharis Stavroulakis	4
10	ALSUntangled #66: antimycobacterial antibiotics. 2022 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Ellen S. Pierce, Paul E. Barkhaus, (unknown), Mark B. Bromberg, Gregory T. Carter, (unknown), David Greeley, (unknown), (unknown), Isaac Lund, Christopher McDermott, Gary L. Pattee, (unknown), Meraida Polak, (unknown), Paul Wicks, Richard Bedlack	1
11	Understanding the current nutritional management for people with amyotrophic lateral sclerosis - A mapping review 2022 ·Clinical Nutrition ESPEN ·Munira Essat, Elizabeth Coates, Mark Clowes, Daniel Beever, (unknown), Sean White, Theocharis Stavroulakis, Vanessa Halliday, Christopher McDermott	4
12	The nutritional management of people living with amyotrophic lateral sclerosis: A national survey of dietitians 2021 ·Journal of Human Nutrition and Dietetics ·Sean White, Nicolò Zarotti, Daniel Beever, Mike Bradburn, Paul Norman, Elizabeth Coates, Theocharis Stavroulakis, David White, (unknown), (unknown), (unknown), Vanessa Halliday, Christopher McDermott, (unknown)	14
13	Improving clinical trial outcomes in amyotrophic lateral sclerosis 2020 ·Nature Reviews Neurology ·Matthew C. Kiernan, Steve Vucic, Kevin Talbot, Christopher McDermott, Orla Hardiman, Jeremy M. Shefner, Ammar Al‐Chalabi, William Huynh, Merit Cudkowicz, Paul Talman, Leonard H. van den Berg, Thanuja Dharmadasa, Paul Wicks, C.M. Reilly, Martin R. Turner	178
14	Interventions to promote oral nutritional behaviours in people living with neurodegenerative disorders of the motor system: A systematic review 2019 ·Clinical Nutrition ·Munira Essat, Rachel Archer, (unknown), Nicolò Zarotti, Elizabeth Coates, Mark Clowes, Daniel Beever, (unknown), Sean White, Theocharis Stavroulakis, David White, Paul Norman, Christopher McDermott	10
15	The optimisation of noninvasive ventilation in amyotrophic lateral sclerosis: a systematic review 2019 ·European Respiratory Journal ·David O’Brien, Theocharis Stavroulakis, Susan Baxter, Paul Norman, Stephen Bianchi, Mark Elliott, Maxine Johnson, Mark Clowes, Aldara García‐Sánchez, Esther Hobson, Christopher McDermott	22
16	Optimizing the noninvasive ventilation pathway for patients with amyotrophic lateral sclerosis/motor neuron disease: a systematic review 2019 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Susan Baxter, Maxine Johnson, Mark Clowes, David O’Brien, Paul Norman, Theocharis Stavroulakis, Stephen Bianchi, Mark Elliott, Christopher McDermott, Esther Hobson	15
17	Neurodegeneration caused by intronic expansions of C9ORF72 is a clinically heterogeneous but pathologically distinct disease 2013 ·The Lancet ·Johnathan Cooper‐Knock, J. Robin Highley, Judith Hartley, Antonio Milano, Stephen Sawcer, (unknown), (unknown), Gavin Charlesworth, Nicholas Wood, Oliver Bandmann, Christopher McDermott, Janine Kirby, Paul G. Ince, Pamela J. Shaw	1
18	Gastrostomy use in motor neurone disease (MND): A review, meta-analysis and survey of current practice 2012 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Theocharis Stavroulakis, Theresa Walsh, Pamela J. Shaw, Christopher McDermott, (unknown)	55
19	How New Zealand adjusts to macroeconomic shocks: implications for joining a currency area 2000 ·Reserve Bank of New Zealand Bulletin ·(unknown), Christopher McDermott	14
20	Cointegration: Origins and significance for economists 1990 ·New Zealand Economic Papers ·Christopher McDermott	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact